Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results.

被引：0
|
作者：
Pinto, C.
Di Fabio, F.
Siena, S.
Cascinu, S.
Llimpe, F. L. Rojas
Ceccarelli, C.
Mutri, V.
Giaquinta, S.
Piana, E.
Martoni, A. A.
机构：
[1] S Orsola M Malpighi Hosp, Med Oncol Unit, Bologna, Italy
[2] Osped Niguarda Ca Granda, Med Oncol Unit, Milan, Italy
[3] Torrette Hosp, Med Oncol Unit, Ancona, Italy
[4] S Orsola M Malpighi Hosp, Pathol Unit, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4031
引用
收藏
页码：186S / 186S
页数：1
相关论文
共 50 条
  • [41] A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC): Preliminary results.
    Garin, A
    Manikhas, A
    Biakhov, M
    Chezhin, M
    Ivanchenko, T
    Krejcy, K
    Karaseva, V
    Tjuyandin, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 51S - 51S
  • [42] FOLFOX (oxaliplatin and leucovorin plus fluorouracil) versus FOLFIRI (irinotecan and leucovorin plus fluorouracil) chemotherapy as a first-line treatment in a patients with unresectable metastatic or recurred gastric adenocarcinoma
    Tak, Dae Hyun
    Kim, Seok Hyun
    Moon, Hee Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 261 - 261
  • [43] GLOW: Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin18.2./HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Xu, R-H.
    Ajani, J. A.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P. C.
    Ilson, D. H.
    Kim, S.
    Lordick, F.
    Shitara, K.
    van Cutsem, E.
    Arozullah, A.
    Park, J. W.
    Shah, M. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1315 - S1316
  • [44] Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Kcnecny, G
    Hecker, D
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [45] Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
    Tabernero, J.
    Van Cussem, E.
    Bang, Y.
    Fuchs, C.
    Wyrwicz, L.
    Lee, K.
    Kudaba, I.
    Garrido, M.
    Chung, C.
    Salguero, C. Castro
    Mansoor, W.
    Braghiroli, M.
    Goekkurt, E.
    Chao, J.
    Wainberg, Z.
    Kher, U.
    Shah, S.
    Karg, S.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 152 - +
  • [46] Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study)
    Li, J.
    Liu, X.
    Wang, B. Y.
    Guo, W. J.
    Lin, J. L.
    Zhu, X. D.
    Zhang, J.
    Liu, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] A phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer: preliminary results.
    Kozloff, M. F.
    Chuang, E.
    Roy, J.
    Starr, A.
    Gowland, P. A.
    Tarpey, M. J.
    Coliler, M.
    Verk, L.
    Kern, K.
    Miller, K.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S273 - S273
  • [48] Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies.
    Kardosh, Adel
    Tseng, Diane
    Sahaf, Bita
    Zomet, Ativ
    Krupa, Julia
    Fisher, George A.
    Wang, David S.
    Mackall, Crystal
    Kunz, Pamela L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Liu, Funan
    Gong, Jifang
    Jin, Zhaoyu
    Zhang, Miao
    Zhang, Shu
    Zhang, Yanqiao
    Liang, Xinjun
    Li, Yun
    Yang, Xiaochun
    Yang, Yaping
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Prognostic significance of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study)
    Llimpe, F. L. Rojas
    Di Fabio, F.
    Ceccarelli, C.
    Pinto, C.
    Siena, S.
    Cascinu, S.
    Funaioli, C.
    Mutri, V.
    Giaquinta, S.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345